Charles G. Drake, MD, PhD, and Daniel Suzman, MD, discuss 2 recent studies and a review article on cancer immunotherapy, as well as how the data relate to current therapeutic paradigms and future directions in the treatment of cancer.
David F. McDermott, MD, and Anasuya Gunturi, MD, PhD, discuss 3 recent studies on cancer immunotherapy, as well as how the data relate to current therapeutic paradigms and future directions in the treatment of cancer.
In this review article, Charles G. Drake, MD, PhD; Evan J. Lipson, MD; and Julie Brahmer, MD, discuss the various clinical approaches and emerging data supporting immunotherapy in melanoma, non-small-cell lung cancer, and renal cell carcinoma.
This slideset briefly summarizes key concepts and recent clinical results regarding immune checkpoint blockade across multiple tumor types including melanoma, lung cancer, kidney cancer, and others.
Pembrolizumab is associated with a low incidence of grade 3/4 toxicities and confirmed response rates by RECIST criteria are similar regardless of previous ipilimumab treatment.
Pembrolizumab is associated with a low incidence of grade 3/4 toxicities and similar response rates regardless of previous ipilimumab treatment.
Ipilimumab after bone-directed radiotherapy failed to significantly prolong overall survival compared with placebo in the intent-to-treat analysis but showed evidence of antitumor activity and stronger benefit in patients with favorable prognostic factors.
Ipilimumab after docetaxel failed to significantly prolong overall survival compared with placebo in the intent-to-treat analysis but showed evidence of antitumor activity and stronger benefit in patients with favorable prognostic factors.
Median PFS of up to 4.2 months using RECIST, and up to 6.9 months using immune-related response criteria, with no dose-response relationship for PFS and median OS higher than predicted by PFS results.
Nivolumab showed evidence of antitumor activity with an approximately 20% ORR across 3 dose levels and a median OS of 18-25 months in patients with clear cell metastatic RCC.
MPDL3280A treatment well tolerated with high response rates among patients with elevated PD-L1 expression on tumor-infiltrating immune cells.
MPDL3280A showed evidence of antitumor activity with a 43% ORR in patients with PD-L1 positive tumor-infiltrating immune cells.
Nivolumab associated with 73% survival rate at 1 year and 58% reduction in risk of death compared with dacarbazine in treatment-naive patients with advanced BRAF wild-type melanoma.
In the CheckMate 066 phase III study, the 1-year survival rate with nivolumab was 73% with a 58% reduction in the risk of death compared with DTIC in previously untreated patients.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.